Novadiscovery announces key collaboration with Janssen France to provide in silico based decision support for clinical development

Novadiscovery announces key collaboration with Janssen France to provide in silico based decision support for clinical development

Lyon, France – 17 December 2020: Novadiscovery, a leading health tech company offering a best-in-class clinical trial simulation platform, Jinkō®, to predict drug efficacy and optimize clinical trial development, today announces that it has entered into a collaboration with Janssen France to provide in silico based decision support for its clinical development pipeline.

Novadiscovery is committed to working with forward-looking industry leaders to improve R&D productivity and maximize patient outcomes through disease modeling and simulation, ahead of human trials.

Regulatory agencies in the US and Europe are working to provide a framework for the expanded use of model-informed drug development (MiDD) to improve clinical trial efficiency and increase the probability of regulatory success.

François-Henri Boissel, CEO, Novadiscovery, commented: “We are proud to have been selected by a leading pharmaceutical company to help provide answers to key clinical development questions in the future of healthcare. We are excited to join with Janssen France as it adopts this new technology and we envisage a long and productive collaboration.”

Philippe Bonnard, Medical Director Oncology, Janssen France, highlighted: “Our strategic goal is to transform drug R&D using innovative digital technologies. In this collaboration with Nova, we look forward to realizing the potential of in silico technology to help us deliver higher quality compounds more effectively.”


For more information, please contact:

François-Henri Boissel, Chief Executive Officer
Email: [email protected]

Consilium Strategic Communications
Sukaina Virji, Melissa Gardiner, Carina Jurs
Email: [email protected]com

About Novadiscovery

Novadiscovery is a leading health tech company using in silico clinical trials to predict drug efficacy and optimize clinical trial development. The Company aims to improve R&D productivity and maximize patient outcomes by predicting the clinical benefit of a potential new drug candidate through computer simulation, ahead of human trials.

Novadiscovery’s innovative approach leverages disease modeling and simulation expertise accumulated over the past decade and combines mathematical models of diseases and potential new treatments with virtual patients in its integrated clinical trial simulation platform, Jinkō®.

Novadiscovery is headquartered in Lyon, France and has a team of around 30 scientists, engineers & clinicians who work at the interface of biology, pharmacology, mathematics & computer science.

For more information, please visit and follow us on Twitter @novadiscovery and

Version française:

Novadiscovery annonce une collaboration stratégique avec Janssen France pour l’accélération de son développement clinique grâce aux essais in silico

Lyon, France – [XX] décembre 2020: Novadiscovery, société leader dans le domaine des technologies de la santé, offrant une plateforme de simulation informatique d’essais cliniques, de prédiction de l’efficacité des médicaments et d’optimisation du développement d’essais cliniques, annonce aujourd’hui qu’elle est entrée dans une collaboration avec Janssen France pour fournir une aide à la décision in silico dans le cadre du développement clinique.

Novadiscovery s’est engagée à travailler avec des leaders de l’industrie tournés vers l’avenir pour améliorer, modéliser et simuler des maladies, avant de conduire les essais chez l’homme. Novadiscovery s’appuie notamment sur une plateforme de simulation d’essais cliniques, Jinkō®.

Les autorités de santé aux États-Unis et en Europe travaillent à la mise en œuvre d’un cadre pour la mise en place d’essais cliniques in silico (ou Model-informed Drug Development MiDD) afin d’améliorer l’efficacité du développement clinique et d’augmenter la probabilité de succès réglementaires.

François-Henri Boissel, PDG de Novadiscovery, a déclaré : « Nous sommes fiers d’avoir été sélectionnés par une entreprise pharmaceutique d’envergure mondiale, qui s’attache à travailler à l’avenir des soins de santé pour apporter des réponses aux questions clés du développement clinique. Nous sommes ravis de nous joindre à Janssen France dans leur adoption de nouvelles technologies et nous envisageons une collaboration longue et productive. »

Philippe Bonnard, Directeur Médical Oncologie chez Janssen France, a affirmé : « Notre objectif stratégique est de faire évoluer la R&D en utilisant des technologies numériques innovantes. Dans le cadre de cette collaboration avec Novadiscovery, nous sommes impatients de pouvoir nous appuyer sur le potentiel de la technologie in silico pour simuler les effets de nos molécules sur une population de patients virtuelle, tout en garantissant la rigueur scientifique, la transparence et la traçabilité totale pour répondre aux critères des agences de réglementation de santé.”

Latest News

TigerGraph Continues to Drive Graph Analytics and AI Market Momentum, Unveils TigerGraph Cloud on Google Cloud Platform and Expanded Global Developer Community

Graph Leader Also Reveals Connectors for Snowflake and Tableau, Announces Hackathon Winners, and Shares Early Release of Graph-Powered Analytics Book at Graph + AI Summit 2021 REDWOOD CITY, Calif., April 21, 2021 (GLOBE NEWSWIRE) — TigerGraph, provider of the leading graph analytics platform, today announced that the company continues to accelerate the adoption, application, and […]

TRIO Completes Enrollment of Phase III NATALEE Breast Cancer Clinical Trial

Over 5000 Patients Enrolled in 20 countries EDMONTON, Alberta, April 21, 2021 (GLOBE NEWSWIRE) — Translational Research In Oncology (TRIO) today announced completion of enrollment for Novartis phase III clinical trial of ribociclib with endocrine therapy in the adjuvant treatment of HR-positive, HER2-negative early breast cancer (EBC). The trial, referred to as NATALEE (New Adjuvant […]

ACAMS’ 12th Annual AML & Anti-Financial Crime Conference – APAC Takes Cutting-Edge Look at the Perils and Promise of Compliance Efforts in the Asia Pacific Region

Financial-crime prevention experts from the Hong Kong Monetary Authority, Monetary Authority of Singapore, Anti-Money Laundering Council (AMLC) of the Philippines, British Consulate-General Hong Kong, Homeland Security Investigations, U.S. Consulate General Hong Kong, and APAC’s leading financial institutions will share mitigation strategies on money laundering, sanctions, corruption, bribery and other regulatory challenges Hong Kong / Singapore, […]